| Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis AW Armstrong, L Puig, A Joshi, M Skup, D Williams, J Li, KA Betts, ... JAMA dermatology 156 (3), 258-269, 2020 | 237 | 2020 |
| Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis AD Dick, N Tundia, R Sorg, C Zhao, J Chao, A Joshi, M Skup Ophthalmology 123 (3), 655-662, 2016 | 184 | 2016 |
| Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay A Deodhar, M Mittal, P Reilly, Y Bao, S Manthena, J Anderson, A Joshi Clinical rheumatology 35, 1769-1776, 2016 | 93 | 2016 |
| Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database D Wendling, A Joshi, P Reilly, YJ Jalundhwala, M Mittal, Y Bao Current medical research and opinion 30 (12), 2515-2521, 2014 | 78 | 2014 |
| Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials J Sheppard, A Joshi, KA Betts, S Hudgens, S Tari, N Chen, M Skup, ... JAMA ophthalmology 135 (6), 511-518, 2017 | 73 | 2017 |
| Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis JE Thorne, M Skup, N Tundia, D Macaulay, C Revol, J Chao, A Joshi, ... Acta Ophthalmologica 94 (5), e331-e339, 2016 | 72 | 2016 |
| ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work … D van der Heijde, A Joshi, AL Pangan, N Chen, K Betts, M Mittal, Y Bao Rheumatology 55 (1), 80-88, 2016 | 72 | 2016 |
| Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data NH Shear, KA Betts, AM Soliman, A Joshi, Y Wang, J Zhao, P Gisondi, ... Journal of the American Academy of Dermatology 85 (3), 572-581, 2021 | 42 | 2021 |
| Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the … EB Suhler, JE Thorne, M Mittal, KA Betts, S Tari, A Camez, Y Bao, A Joshi Ophthalmology 124 (12), 1799-1807, 2017 | 37 | 2017 |
| Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis JI Silverberg, HC Hong, JP Thyssen, BM Calimlim, A Joshi, HD Teixeira, ... Dermatology and therapy 12 (5), 1181-1196, 2022 | 36 | 2022 |
| Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials M Augustin, J Lambert, C Zema, EHZ Thompson, M Yang, EQ Wu, ... JAMA dermatology 156 (12), 1344-1353, 2020 | 36 | 2020 |
| Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison V Strand, KA Betts, M Mittal, J Song, M Skup, A Joshi Rheumatology and therapy 4, 349-362, 2017 | 26 | 2017 |
| Network meta-analysis and cost per responder of tumor necrosis factor-α and interleukin inhibitors in the treatment of active ankylosing spondylitis KA Betts, J Griffith, Y Song, M Mittal, A Joshi, EQ Wu, A Ganguli Rheumatology and Therapy 3, 323-336, 2016 | 26 | 2016 |
| Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom AD Joshi, JA Carter, MF Botteman, S Kaura Clinical therapeutics 33 (3), 291-304. e8, 2011 | 23 | 2011 |
| OP0115 Relative Efficacy of Adalimumab versus Secukinumab in Active Ankylosing Spondylitis: A Matching-Adjusted Indirect Comparison KA Betts, M Mittal, J Song, M Skup, A Joshi Annals of the Rheumatic Diseases 75 (Suppl 2), 98-99, 2016 | 16 | 2016 |
| Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or … KS Kolibaba, JA Sterchele, AD Joshi, M Forsyth, E Alwon, H Beygi, ... Therapeutic Advances in Hematology 4 (3), 157-171, 2013 | 16 | 2013 |
| Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours JA Carter, AD Joshi, S Kaura, MF Botteman Pharmacoeconomics 30, 373-386, 2012 | 16 | 2012 |
| Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands JA Carter, A Joshi, S Kaura, MF Botteman Journal of medical economics 14 (3), 288-298, 2011 | 16 | 2011 |
| Utilization patterns of IV iron and erythropoiesis stimulating agents in anemic chronic kidney disease patients: a multihospital study AD Joshi, DA Holdford, DF Brophy, SE Harpe, D Mays, TWB Gehr Anemia 2012 (1), 248430, 2012 | 15 | 2012 |
| Media coverage of off-label promotion: A content analysis of US newspapers AD Joshi, DA Patel, DA Holdford Research in Social and Administrative Pharmacy 7 (3), 257-271, 2011 | 15 | 2011 |
Keith BettsAnalysis Group, Inc.在 analysisgroup.com 的电子邮件经过验证
